Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of...

Full description

Bibliographic Details
Main Authors:	Hugo Marcel Vanderstichele, Charlotte E. Teunissen, Eugeen Vanmechelen
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2019-12-01
Series:	Neurology and Therapy
Subjects:	Assay Blood Biomarker panel β-Amyloid Tau Validation
Online Access:	https://doi.org/10.1007/s40120-019-00166-3

id	doaj-83571f756cab49beacbdcbeb6dfb0727
record_format	Article
spelling	doaj-83571f756cab49beacbdcbeb6dfb07272020-12-13T12:14:16ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362019-12-018S212914510.1007/s40120-019-00166-3Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical EnvironmentHugo Marcel Vanderstichele0Charlotte E. Teunissen1Eugeen Vanmechelen2BiomarkableAmsterdam University CenterKey4ADAbstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD).https://doi.org/10.1007/s40120-019-00166-3AssayBloodBiomarker panelβ-AmyloidTauValidation
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Hugo Marcel Vanderstichele Charlotte E. Teunissen Eugeen Vanmechelen
spellingShingle	Hugo Marcel Vanderstichele Charlotte E. Teunissen Eugeen Vanmechelen Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment Neurology and Therapy Assay Blood Biomarker panel β-Amyloid Tau Validation
author_facet	Hugo Marcel Vanderstichele Charlotte E. Teunissen Eugeen Vanmechelen
author_sort	Hugo Marcel Vanderstichele
title	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_short	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_full	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_fullStr	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_full_unstemmed	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_sort	critical steps to be taken into consideration before quantification of β-amyloid and tau isoforms in blood can be implemented in a clinical environment
publisher	Adis, Springer Healthcare
series	Neurology and Therapy
issn	2193-8253 2193-6536
publishDate	2019-12-01
description	Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD).
topic	Assay Blood Biomarker panel β-Amyloid Tau Validation
url	https://doi.org/10.1007/s40120-019-00166-3
work_keys_str_mv	AT hugomarcelvanderstichele criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment AT charlotteeteunissen criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment AT eugeenvanmechelen criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment
_version_	1724385051164016640

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Similar Items